Amid today's historically expensive market, there are still a host of health care and energy companies that are attractively priced for investors. Stocks have had an impressive run this year, with the Dow Jones Industrial Average and S & P 500 ending November trading on a strong note, touching all-time highs this past week. The 30-stock Dow added 1.4% in the latest week while the the S & P 500 and Nasdaq Composite indexes both rose 1.1%.
-based company has seen rising sales of Leqembi, its breakthrough Alzheimer's drug, as well as new rare disease and depression treatments. Another biotech, Regeneron Pharmaceuticals , also turned up on the screen. The stock has plunged 29% so far this quarter and is now down nearly 15% this year. But based on analysts' consensus target, Regeneron could return about 44% over the coming year.